441 related articles for article (PubMed ID: 28229895)
21. Dyskinesias and levodopa therapy: why wait?
Matarazzo M; Perez-Soriano A; Stoessl AJ
J Neural Transm (Vienna); 2018 Aug; 125(8):1119-1130. PubMed ID: 29428995
[TBL] [Abstract][Full Text] [Related]
22. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
23. [Impulsive-compulsive syndrome in Parkinson's disease].
Nikitina AV; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
[TBL] [Abstract][Full Text] [Related]
24. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
Stathis P; Konitsiotis S; Antonini A
Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
[TBL] [Abstract][Full Text] [Related]
25. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
26. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
[TBL] [Abstract][Full Text] [Related]
27. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
28. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
[TBL] [Abstract][Full Text] [Related]
29. Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease.
Girard R; Obeso I; Thobois S; Park SA; Vidal T; Favre E; Ulla M; Broussolle E; Krack P; Durif F; Dreher JC
Brain; 2019 Jan; 142(1):146-162. PubMed ID: 30590514
[TBL] [Abstract][Full Text] [Related]
30. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
Rocha MS; Andrade LA; Ferraz HB; Borges V
Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
[TBL] [Abstract][Full Text] [Related]
31. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
Bienfait KL; Menza M; Mark MH; Dobkin RD
J Clin Neurosci; 2010 Apr; 17(4):539-40. PubMed ID: 20171891
[TBL] [Abstract][Full Text] [Related]
32. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.
Hinkle JT; Perepezko K; Rosenthal LS; Mills KA; Pantelyat A; Mari Z; Tochen L; Bang JY; Gudavalli M; Yoritomo N; Butala A; Bakker CC; Johnson V; Moukheiber E; Dawson TM; Pontone GM
Parkinsonism Relat Disord; 2018 Feb; 47():50-56. PubMed ID: 29198499
[TBL] [Abstract][Full Text] [Related]
33. Impulse Control Disorders in the Polish Population of Patients with Parkinson's Disease.
Toś M; Grażyńska A; Antoniuk S; Siuda J
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629758
[No Abstract] [Full Text] [Related]
34. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
[TBL] [Abstract][Full Text] [Related]
35. Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Marano M; Naranian T; di Biase L; Di Santo A; Poon YY; Arca R; Cossu G; Marano P; Di Lazzaro V; Fasano A
Parkinsonism Relat Disord; 2019 Dec; 69():140-146. PubMed ID: 31759188
[TBL] [Abstract][Full Text] [Related]
36. Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
Niccolini F; Loane C; Politis M
Eur J Neurol; 2014 May; 21(5):694-9, e39-43. PubMed ID: 24471508
[TBL] [Abstract][Full Text] [Related]
37. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
[TBL] [Abstract][Full Text] [Related]
38. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
39. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
40. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
